PowerPoint Slides for: The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy
Brown L.C.
Jobson M.A.
Payan Schober F.
Chang E.H.
Falk R.J.
Nachman P.H.
Pendergraft W.F.
10.6084/m9.figshare.4775635.v1
https://karger.figshare.com/articles/dataset/PowerPoint_Slides_for_The_Evolving_Role_of_Rituximab_in_Adult_Minimal_Change_Glomerulopathy/4775635
<p><b><i>Background:</i></b> Minimal-change glomerulopathy is defined
histologically by the presence of normal glomeruli on light microscopy
and diffuse podocyte effacement on electron microscopy. Although
effective in children, corticosteroid treatment in adults is more
variable and time to response can be prolonged. Data to support
rituximab use in adults with corticosteroid-dependent or resistant
minimal-change glomerulopathy are limited. Here, we describe the
clinical course of adults with corticosteroid-dependent or -resistant
minimal-change glomerulopathy who received rituximab. <b><i>Methods:</i></b>
Demographic and clinical data were collected and analyzed from all
adult patients with native kidney, biopsy-proven, minimal-change
glomerulopathy who were administered rituximab between 2009 and 2014 and
cared for at the UNC Kidney Center. <b><i>Results:</i></b> Ten patients with corticosteroid-resistant (<i>n</i> = 5) or corticosteroid-dependent (<i>n</i>
= 5) idiopathic minimal-change glomerulopathy were treated with
rituximab between 2009 and 2014. Rituximab treatment induced remission
in all 10 patients with a median time to remission of 2 months. The
median time from rituximab to corticosteroid discontinuation was 3.5
months. The median remission time was 29 months and follow-up time was
39.5 months. No serious adverse events attributable to rituximab were
observed. <b><i>Conclusion:</i></b> Rituximab induced remission in all
patients with corticosteroid-dependent or -resistant minimal-change
glomerulopathy, and may hold great therapeutic potential with good
efficacy and minimal toxicity. Mounting evidence implies that a
well-conducted randomized controlled clinical trial using rituximab in
adults with minimal-change glomerulopathy in both
corticosteroid-resistant and corticosteroid-dependent patients is
warranted.</p>
2017-03-22 13:26:33
Minimal change glomerulopathy
Rituximab
Outcomes